Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 3 records in total 3
    records per page

    Potential involvement of monoamine oxidase activity in SARS-COV2 infection MESHD and delirium MESHD delirium HP onset

    Authors: Miroslava Cuperlovic-Culf; Emma L Cunningham; Anuradha Surendra; Xiaobei Pan; Steffany A.L. Bennett; Mijin Jung; Bernadette McGuiness; Anthony Peter Passmore; Danny McAuley; David Beverland; Brian D. Green

    doi:10.1101/2020.06.16.20128660 Date: 2020-06-19 Source: medRxiv

    Abstract Severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) causes a range of extra- respiratory signs and symptoms MESHD. One such manifestation is delirium MESHD delirium HP, an acute confusional state occurring in 60-70% of severe SARS-CoV-2 cases. Delirium MESHD Delirium HP is also a common clinical syndrome MESHD following planned orthopedic surgery. This investigation initially explored the underlying role of metabolism in delirium MESHD delirium HP-susceptibility in this setting. Metabolomics profiles of cerebrospinal fluid (CSF) and blood SERO taken prior to surgery found significant concentration differences of several amino acids, acylcarnitines and polyamines were observed in delirium MESHD delirium HP-prone patients. Phenethylamine (PEA) concentrations in delirium MESHD delirium HP-prone patients was significantly lower in CSF than in blood SERO, whilst in age TRANS- and gender TRANS-matched controls the opposite was observed (adjusted p values: 1.8x10-6 (control) and 1.788x10-10 ( delirium MESHD delirium HP)). PEA is metabolised by monoamine oxidase B (MAOB), a putative enzyme target for the treatment of Alzheimers disease MESHD Alzheimers disease HP, Parkinsons disease MESHD and depression. Our computational structural comparisons of MAOB and angiotensin converting enzyme (ACE) 2 found high similarity, specifically within the SARS-CoV-2 spike protein. MAOB structural alignment to ACE2 was 51% overall, but this was over 95% in the ACE2-spike protein binding region. Thus, it is possible that the spike protein interacts with MAOB on a molecular level. A previously published metabolomic dataset of control subjects and patients with either mild or severe COVID-19 was then analysed. Major concentration differences in some metabolites attributed to altered MAO activity were detected. Therefore, our hypothesis is that the SARS-CoV-2 influences MAOB activity, which is one potential cause for the many observed neurological and platelet based complications of SARS-CoV-2 infection MESHD. Further research is required to establish what effect MAOB inhibitors might have on these pathways. There is no evidence at present to support the withholding of MAOB inhibitors.

    An Update on SARS-COV-2/COVID-19 with Particular Reference on Its Clinical Pathology, Pathogenesis, Immunopathology and Mitigation Strategies – A Review

    Authors: Kuldeep Dhama; Shailesh Kumar Patel; Mamta Pathak; Mohd. Iqbal Yatoo; Ruchi Tiwari; Yashpal Singh Malik; Rajendra Singh; Ranjit Sah; Ali A. Rabaan; D. Katterine Bonilla-Aldana; Alfonso J. Rodriguez-Morales

    id:10.20944/preprints202003.0348.v1 Date: 2020-03-23 Source:

    Coronavirus Disease MESHD 2019 (COVID-19), caused by a novel coronavirus named Severe Acute Respiratory Syndrome MESHD - Coronavirus-2 (SARS-CoV-2), emerged in early December 2019 in China and attained a pandemic situation worldwide by its rapid spread to nearly 167 countries with 287.239 confirmed cases TRANS and 11.921 human deaths MESHD with a case fatality rate (CFR) of around 4 per cent. Bats were considered as the reservoir host, and the search of a probable intermediate host is still going on. Animals have anticipated culprit of SARS-CoV-2 as of now. The disease MESHD is mainly manifested by pneumonia MESHD pneumonia HP and related respiratory signs and symptoms MESHD, but the involvement of the gastrointestinal system and nervous system is also suggested. The severe form of the disease MESHD associated with death MESHD is mainly reported in older and immune-compromised patients with pre-existing disease MESHD history. Death MESHD in severe cases is attributed to respiratory failure HP associated with hyperinflammation. Cytokine storm syndrome MESHD associated with rampant inflammation MESHD in response to SARS-CoV-2 infection MESHD is considered as the leading killer of COVID-19 patients. COVID-19 patients were reported with higher levels of many pro-inflammatory cytokines and chemokines like IFN-g, IL-1b, IP-10, and MCP-1. Furthermore, severe cases of COVID-19 revealed higher levels of TNF-α, G-CSF, and MIP-1A. Blood SERO profile of the COVID-19 patients exhibits lymphopenia MESHD lymphopenia HP, leucopenia, thrombocytopenia MESHD thrombocytopenia HP and RNAaemia along with increased levels of aspartate aminotransferase. SARS-CoV-2 infection MESHD in pregnant women does not lead to fetus mortalities unlike other zoonotic coronaviruses like SARS-CoV and MERS-CoV, with no evidence of intrauterine transmission TRANS to neonates. Rapid and confirmatory diagnostics have been developed, and high efforts are being made to develop effective vaccines and therapeutics. In the absence of any virus-specific therapeutic, internationally health care authorities are recommending adoption of effective prevention and control measures to counter and contain this pandemic virus. This paper is an overview of this virus and the disease MESHD with a particular focus on SARS-COV-2 / COVID-19 clinical pathology, pathogenesis and immunopathology along with a few recent research developments.

    Efficacy of Dao Yin in patients with 2019 novel coronavirus pneumonia MESHD pneumonia HP: study protocol for a randomized controlled trial

    Authors: Shuaipan Zhang; Zhizhen Lv; Qingguang Zhu; Wuquan Sun; Fei Yao; Lei Fang; Lingjun Kong; Yanbin Cheng; Zhiwei Wu; Min Fang

    doi:10.21203/ Date: 2020-02-28 Source: ResearchSquare

    Background The epidemic of 2019 novel coronavirus (2019-nCoV) pneumonia MESHD pneumonia HP has become a focused public health event in world. The authorities have taken prompt medical action in China, which contained strict isolation measures and potential symptomatic supportive care. Dao Yin, a traditional Chinese exercise, combines limb movements and breathing exercises. Previous researches showed that it can activate the immune system and improve the lung function and the mental state of patients. Therefore, there may be a potential effect of Dao Yin on the physical and mental health of patients with 2019-nCoV. The aim of this trail is to verify whether conventional therapy plus Dao Yin could show better effects for 2019-nCoV than conventional therapy alone.Methods/design The study is a multicenter randomized controlled trial with parallel-group design including two intervention groups: a conventional therapy group and a conventional therapy plus Dao Yin group. A total of 186 eligible participants will be randomly assigned to the groups in a 1:1 ratio. The routine treatment of the two groups is performed daily according to guideline, and Dao Yin is performed once a day until the patient is out of the hospital. The primary outcome is the Length of Hospital Stay (LHS). Secondary outcomes include the vital signs, respiratory symptoms MESHD, questionnaire of mental health and the quantity of immune cells. The outcomes will be assessed at five points including the baseline, 3th, 6th, 9th day during hospitalization and the discharge day. The significance level is 5%. This study will focus on the value of a conventional therapy plus Dao Yin as the treatment for 2019-nCoV and will explore any potential connection among the outcomes.Discussion This study may evaluate the efficacy of conventional therapy plus Dao Yin for 2019-nCoV, which can contribute to provide a solid evidence of Dao Yin therapy for the nationwide emergence.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000029978 Registered on 18 February 2020.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.